Dr. Michael Weinstein interviews Dr. Andreas Muehler, chief medical officer of Immunic Therapeutics, which is developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

At United European Gastroenterology Week, Immunic presented data from the company’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator used to treat celiac disease. Immunic’s new approach to treatment entails restoring a healthy gut wall by modulating SIRT6, a stress responsive protein that helps repair our cells.

Join Dr. Weinstein and Dr. Muehler as they explore the challenges faced by patients with celiac disease and new innovations that will impact the way physicians treat their patients.

Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

Original score by Hayden Margolis

Gastro Broadcast, Episode 51